| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1928388 | Biochemical and Biophysical Research Communications | 2014 | 6 Pages |
Abstract
In conclusion, vernakalant activates K2P17.1 background potassium channels. Pharmacologic K2P channel activation by cardiovascular drugs has not been reported previously and may be employed for personalized rhythm control in patients with AF-associated reduction of K+ channel function.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Claudia Seyler, Patrick A. Schweizer, Edgar Zitron, Hugo A. Katus, Dierk Thomas,